Atopic Dermatitis Drugs Market by Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids), Route of Administration (Injectable ROA, Oral ROA, Tropical ROA) - Global Forecast 2024-2030
The Atopic Dermatitis Drugs Market size was estimated at USD 8.02 billion in 2023 and expected to reach USD 8.56 billion in 2024, at a CAGR 6.84% to reach USD 12.76 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Atopic Dermatitis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Atopic Dermatitis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Atopic Dermatitis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma S.A., GlaxoSmithKline PLC, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage
This research report categorizes the Atopic Dermatitis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drug Class
Biologics
Injectable ROA
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Atopic Dermatitis Drugs Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Atopic Dermatitis Drugs Market?
- What are the technology trends and regulatory frameworks in the Atopic Dermatitis Drugs Market?
- What is the market share of the leading vendors in the Atopic Dermatitis Drugs Market?
- Which modes and strategic moves are suitable for entering the Atopic Dermatitis Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Atopic Dermatitis Drugs Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing incidence of atopic dermatitis
- 5.1.1.2. Growing prevalence of food allergies intensifying atopic dermatitis
- 5.1.1.3. Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
- 5.1.2. Restraints
- 5.1.2.1. High cost of therapeutics
- 5.1.3. Opportunities
- 5.1.3.1. Rising awareness regarding the availability of treatments for the disease
- 5.1.3.2. Growing access to treatment in various developing countries
- 5.1.4. Challenges
- 5.1.4.1. Adverse effects associated with the use of medication
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Atopic Dermatitis Drugs Market, by Drug Class
- 6.1. Introduction
- 6.2. Biologics
- 6.3. Calcineurin Inhibitors
- 6.4. Corticosteroids
- 6.5. Phosphodiesterases 4 Inhibitors
- 7. Atopic Dermatitis Drugs Market, by Route of Administration
- 7.1. Introduction
- 7.2. Injectable ROA
- 7.3. Oral ROA
- 7.4. Tropical ROA
- 8. Americas Atopic Dermatitis Drugs Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Atopic Dermatitis Drugs Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa Atopic Dermatitis Drugs Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. AbbVie Inc.
- 12.1.2. Bausch Health Companies Inc.
- 12.1.3. Bayer AG
- 12.1.4. Biofrontera AG
- 12.1.5. Bristol-Myers Squibb Company
- 12.1.6. Eli Lilly and Company
- 12.1.7. F. Hoffmann-La Roche Ltd.
- 12.1.8. Galderma S.A.
- 12.1.9. GlaxoSmithKline PLC
- 12.1.10. LEO Pharma A/S
- 12.1.11. Meda AB
- 12.1.12. Mylan N.V.
- 12.1.13. Novartis AG
- 12.1.14. Pfizer Inc.
- 12.1.15. Regeneron Pharmaceuticals, Inc
- 12.1.16. Sanofi S.A.
- 12.1.17. Teva Pharmaceutical Industries Ltd.
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. ATOPIC DERMATITIS DRUGS MARKET RESEARCH PROCESS
- FIGURE 2. ATOPIC DERMATITIS DRUGS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ATOPIC DERMATITIS DRUGS MARKET DYNAMICS
- FIGURE 7. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 8. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 10. ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook